Valuation: Insmed Incorporated

Market Cap 28.73B 24.93B 23.35B 21.36B 40.32B 2,737B 40.84B 273B 107B 1,367B 108B 106B 4,551B P/E 2026 *
-50.7x
P/E 2027 * 217x
Enterprise Value 28.05B 24.35B 22.8B 20.85B 39.37B 2,672B 39.88B 267B 105B 1,335B 105B 103B 4,444B EV / Sales 2026 *
16x
EV / Sales 2027 * 9.81x
Free-Float
99.48%
Yield 2026 *
-
Yield 2027 * -
1 day+33.86%
1 week+30.60%
Current month+34.43%
1 month+18.84%
3 months-3.31%
6 months-11.55%
Current year-23.84%
1 week 96.42
Extreme 96.42
137.7
1 month 96.42
Extreme 96.42
137.7
Current year 90.39
Extreme 90.39
186.19
1 year 90.39
Extreme 90.39
212.75
3 years 21.21
Extreme 21.21
212.75
5 years 16.04
Extreme 16.04
212.75
10 years 10.21
Extreme 10.21
212.75
Manager TitleAgeSince
Chief Executive Officer 57 2012-09-09
Director of Finance/CFO 45 2020-01-30
Chief Tech/Sci/R&D Officer 62 2019-12-18
Director TitleAgeSince
Chairman 75 2009-06-15
Chairman 57 2018-11-07
Director/Board Member 72 2014-05-28
Date Insider Type Main position Quantity % Market Cap.
7/23/26 Fiscal year

Chief Executive Officer

32,100 0.0148%
7/9/26 Fiscal year

Chief Executive Officer

32,097 0.0148%
7/6/26 Fiscal year

Chief Technology Officer

36,906 0.0170%
Change 5-day change 1-year change 3-year change Capi.($)
+33.86%+30.60%+19.14%+502.77% 21.46B
-3.25%+13.72%+52.49%+88.86% 64.9B
+0.69%+0.96%+29.39%+68.41% 54.05B
-1.07%-1.79%-18.07%-14.36% 23.16B
+6.43%+13.78%+46.84%+0.52% 21.25B
-0.79%+1.79%+36.31%-25.84% 17.94B
-3.37%+25.85%+213.21%+369.13% 17.03B
+3.84%+9.24%+32.19%+665.94% 14.99B
-7.94%-6.74%+38.42%+157.52% 14.25B
-1.24%-1.71%+426.24%+171.18% 12.28B
Average +2.75%+5.74%+87.62%+198.41% 26.13B
Weighted average by Cap. +2.02%+6.56%+63.25%+153.39%

Financials

2026 *2027 *
Net sales 1.75B 1.52B 1.43B 1.3B 2.46B 167B 2.49B 16.68B 6.55B 83.52B 6.59B 6.45B 278B 2.81B 2.44B 2.29B 2.09B 3.95B 268B 4B 26.74B 10.5B 134B 10.56B 10.33B 446B
Net income -570M -495M -463M -424M -800M -54.31B -810M -5.42B -2.13B -27.13B -2.14B -2.09B -90.32B 40.64M 35.27M 33.03M 30.21M 57.03M 3.87B 57.78M 386M 152M 1.93B 153M 149M 6.44B
Net Debt -676M -587M -549M -502M -948M -64.38B -961M -6.43B -2.52B -32.17B -2.54B -2.48B -107B -1.12B -976M -914M -836M -1.58B -107B -1.6B -10.69B -4.2B -53.54B -4.22B -4.13B -178B
Logo Insmed Incorporated
Insmed Incorporated specializes in the research and development of drugs for the treatment of respiratory, immunological, inflammatory, neurological, and rare diseases. At the end of 2025, the group has two products in the commercialization phase: ARIKAYCE® for the treatment of lung infection caused by the Mycobacterium avium complex and BRINSUPRI® for the treatment of bronchiectasis (dilation of the bronchi) unrelated to cystic fibrosis. The United States account for 74.7% of net sales.
Employees
1,664
Date Price Change Volume
26-08-06 US$132.55 +33.86% 12,032,470
26-08-05 US$99.02 +0.27% 4,899,602
26-08-04 US$98.75 +0.30% 4,290,804
26-08-03 US$98.45 -0.15% 3,546,860
26-07-31 US$98.60 -2.85% 2,902,595
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
132.55USD
Average target price
197.45USD
Spread / Average Target
+48.97%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. INSM Stock